MindWalk verstärkt Geschäftsleitung mit drei Senior-Ernennungen in Boston-Entwicklungsteam

• MindWalk: Zachary Maben zum Director, Antigen Discovery & Protein Engineering berufen; zuvor Principal Scientist bei Arbor Biotechnologies, davor Pfizer.
• Joanne Lim wird Director, Preclinical Development; zuletzt bei Orum Therapeutics, zuvor Codiak Biosciences und Novartis Institutes for BioMedical Research.
• Shuji Sato erweitert als Vice President, Innovative Solutions seinen Zuständigkeitsbereich auf die Pipeline; zuvor Dragonfly Therapeutics und Pfizer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MindWalk Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261014746456) on October 14, 2026, and is solely responsible for the information contained therein.